Professor Michelle Haber is Executive Director of Children’s Cancer Institute, and Head of the Institute’s Experimental Therapeutics Program. She is internationally recognised for her world-class research into the treatment of neuroblastoma and acute lymphoblastic leukaemia in children. Her project team are working towards more effective treatments for individual childhood cancers by identifying molecular targets that drive the growth and development of cancer in children, developing new drugs to inhibit the action of these targets, and combining existing and new drug treatments into novel therapeutic approaches that can be rapidly translated into national and international clinical trials. She has received numerous awards for her research, particularly in terms of translating her research findings into the clinic, including the 2014 Cancer Institute NSW Premier’s Award for Outstanding Cancer Researcher of the Year and in 2015 was appointed an inaugural Fellow of the Australian Academy of Health and Medical Sciences. She was one of three Finalists for the 2017 CSIRO Eureka Prize for Leadership in Innovation and Science. Prof Haber has a long and continuous record of peer-reviewed grant funding and an excellent track record with more than 175 journal publications. She is currently leading the Zero Childhood Cancer national child cancer personalised medicine program, which will enable all newly-diagnosed, high-risk childhood cancer patients in Australia, and all children who relapse following treatment, to have their therapy tailored to the specific genetic and biological characteristics of their individual tumour. The national clinical trial for this program was opened in September 2017.